Relebactam

CHEMBL3301605 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

348.4 g/mol

LogP

-3.6

Phase

4

Relebactam is a bicyclic diamine beta-lactamase inhibitor of the diazabicyclooctane (DBO) class that inactivates class A and class C beta-lactamases, including KPC carbapenemases, by forming a covalent acyl-enzyme complex and preventing hydrolytic cleavage of the beta-lactam ring. It is used in combination with imipenem-cilastatin to extend the spectrum against multidrug-resistant Gram-negative organisms including KPC-producing Klebsiella pneumoniae and Pseudomonas aeruginosa.

Peso molecular

348,3800 g/mol

LogP

-3,60

TPSA

137,00 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Enfermedad infecciosa Hematología Obesidad Oncología

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O.O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O

InChI

InChI=1S/C12H20N4O6S.H2O/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21;/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21);1H2/t9-,10+;/m1./s1

Molecular Formula

C12H20N4O6S

HBD / HBA

3 / 7

Enlaces Rotables

4

Átomos Pesados

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Relebactam is a bicyclic diamine beta-lactamase inhibitor of the diazabicyclooctane (DBO) class that inactivates class A and class C beta-lactamases, including KPC carbapenemases, by forming a covalent acyl-enzyme complex and preventing hydrolytic cleavage of the beta-lactam ring. It is used in combination with imipenem-cilastatin to extend the spectrum against multidrug-resistant Gram-negative organisms including KPC-producing Klebsiella pneumoniae and Pseudomonas aeruginosa.

Yes, Relebactam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301605. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 44129647. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Relebactam en PillFYI

Estructura

Datos Rápidos

Fórmula: C12H20N4O6S
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.